What are the fundraising trends in the biotechnology market?

In our biotechnology market deck, you will find everything you need to understand the market

This chart, featured in our biotechnology market deck, breaks down revenue across customer segments in the biotechnology market

Is more or less capital going into the biotechnology market?

More capital went into the biotechnology market in the last complete year, but the freshest signal is slightly weaker. Full-year 2025 was materially stronger than full-year 2024, with disclosed equity funding rising from about $6.8B to about $17.3B and deal count increasing from 41 to 139.

That full-year comparison is the cleaner structural read because both years are complete. It shows that the biotechnology market did not merely stabilize after a weaker period; it widened meaningfully across companies, stages, and investor syndicates.

So far in 2026, the tone is more cautious. The biotechnology market has raised about $5.9B across 54 deals, compared with about $6.3B across 48 deals over the comparable period in 2025. That means capital is down modestly year over year, even though more companies are getting financed.

The real signal is not collapse. It is check-size normalization. Average round size declined from about $131M in the comparable 2025 period to about $109M so far in 2026, and median round size declined from about $99M to about $86M.

The practical takeaway is that the biotechnology market is still active, but investors are being somewhat more disciplined on round size. More companies are raising capital, but the market is no longer relying as heavily on a few very large financings to carry the headline total.

For the full dataset behind the capital, deal-count, and year-to-date comparisons, see the full biotechnology market report.

Is biotechnology funding activity driven by more deals or larger rounds?

Biotechnology funding activity is currently being driven more by more deals than by larger rounds. So far in 2026, the biotechnology market has more deals than over the comparable 2025 period, but less total capital and smaller average and median rounds.

That combination is important. If activity were being driven by larger rounds, total capital would rise faster than deal count, or average round size would increase. The opposite happened: deal count rose from 48 to 54, while capital fell from about $6.3B to about $5.9B.

The same pattern appears in the full-year comparison. In 2024, the dataset had 41 deals with an average round size of about $165M and a median round size of about $120M. In 2025, the market had 139 deals, but the average round fell to about $124M and the median fell to about $100M.

That means the expansion from 2024 to 2025 was also driven by broader deal activity, not simply bigger biotech rounds. The biotechnology market moved from a narrower set of large financings toward a wider set of institutional-scale rounds.

The caution is that these are still large rounds in absolute terms. So far in 2026, 49 of the 54 identified deals were above $50M, and 26 were above $100M. The correct conclusion is not that biotech rounds are small; it is that they are smaller than the unusually large benchmarks set in 2024 and early 2025.

Is biotechnology capital moving toward later-stage or earlier-stage companies?

Biotechnology capital is moving modestly toward later-stage companies in the freshest period, even though early-stage company formation remains strong. So far in 2026, late-stage financings, defined as Series B and beyond plus growth equity, captured about 55% of capital.

Over the comparable period in 2025, early-stage and later-stage capital were much closer to balanced. Seed plus Series A represented about $2.7B, while Series B and later represented about $2.8B. In 2026, early-stage capital is about $2.6B, while later-stage capital is about $3.2B.

The deal-count evidence is more nuanced. Series A is still the largest stage by deal count so far in 2026, with 19 deals, followed by Series B with 17 deals. That means new company formation has not disappeared from the biotechnology market.

The reason the capital mix looks later-stage is that later-stage rounds are bigger. Series D+ rounds so far in 2026 had an average size of about $206M and a median of about $209M, far above the Series A median of about $78M.

The honest interpretation is that the biotechnology market is funding both formation and validation. Investors still want new platforms and new assets, but the largest checks are moving toward companies with more proof, clearer clinical paths, or more advanced development milestones.

This chart, featured in our biotechnology market deck, compares the main business model options for biotech platform companies

Is the biotechnology market maturing or still experimental?

The biotechnology market is maturing financially, but it remains experimental scientifically. The strongest evidence of maturation is broader deal activity, lower concentration, meaningful later-stage capital, and a less winner-dominated funding structure.

In 2024, the top 10 deals captured about 52% of all capital in the public dataset, the largest deal alone captured about 15%, and the bottom half of deals captured only about 4%. That is a narrow market where a few perceived winners define the story.

In 2025, the structure changed. The top 10 deals captured only about 22% of capital, the largest deal captured about 4%, and the bottom half of deals captured about 28%. That looks much more like an ecosystem than a handful of company-creation events.

So far in 2026, the biotechnology market has preserved much of that maturity. The top 10 rounds account for about 37% of capital, the largest round accounts for about 5%, and the bottom half of deals accounts for about 30%.

But the market is still experimental because early-stage rounds remain unusually large and technically ambitious. Seed rounds averaged about $120M so far in 2026, Series A rounds averaged about $96M, and first financings accounted for about 43% of deals. In biotechnology, that usually reflects asset-backed company formation, platform science, and syndicate conviction rather than low-risk operating businesses.

For deeper analysis of how concentration, stage mix, and round-size compression interact, see the deeper analysis of the biotechnology market.

Are new startups still entering the biotechnology market?

Yes, new startups are still entering the biotechnology market, but the pace is not accelerating dramatically. So far in 2026, first financings represent about 43% of deals and about 42% of capital.

That is a healthy new-company formation signal. The biotechnology market is not simply recycling capital into older portfolio companies; 23 of the 54 identified year-to-date 2026 deals were first financings.

The comparison with early 2025 is useful. Over the comparable period in 2025, first financings represented about 35% of deals and about 48% of capital. So in 2026, more of the deal count is first-time financing, but first financings are slightly less dominant in capital terms.

The longer view adds context. In 2024, first financings accounted for about 49% of deals and about 62% of capital, helped by very large launch rounds. In 2025, first financings accounted for about 35% of deals and about 38% of capital. The market has moved from launch-round intensity toward a more balanced mix.

The practical takeaway is that startup entry is alive but more selective. New biotechnology companies are still being created where they have strong assets, experienced founders, credible platforms, or major investor sponsorship, but the market is less willing than 2024 to let giant launch financings define the entire category.

Are more investors entering the biotechnology market?

More investors appear to be active in the biotechnology market than in 2024, but the freshest 2026 signal is better described as broad participation by an already deep investor base. The evidence proves breadth; it does not prove that every participant is a brand-new biotech investor.

Full-year 2025 had roughly 469 raw disclosed investor strings and around 35 to 45 unique tier-1 investors, compared with roughly 95 disclosed investors in the 2024 public dataset. That expansion matters because the market cannot support 139 large private biotech rounds unless many specialists, strategics, crossover investors, and generalists are willing to participate.

So far in 2026, roughly 254 disclosed investors and about 65 tier-1 investors appear across only four months of activity. That is a large number for a partial year, although it should be read carefully because normalization methods and source coverage can affect the count.

The repeated presence of RA Capital, Janus Henderson, OrbiMed, Qiming, Frazier, Forbion, BVF, Novo Holdings, Pfizer Ventures, SR One, and others shows that the biotechnology market has not narrowed back to a small club of insiders.

So yes, more investors are active than in the weaker 2024 environment. But the more defensible conclusion is that investor participation is broad and durable, not that the market is being flooded by entirely new entrants.

This chart, featured in our biotechnology market deck, illustrates yearly funding for biotechnology startups

Are top investors getting more or less active in biotechnology?

Top investors are getting more active in absolute participation, but less dominant in capital control. In 2025 and early 2026, leading biotechnology investors appeared across many more deals than in 2024, while the share of capital captured by the largest rounds declined sharply versus 2024.

In 2024, RA Capital appeared in at least 9 deals and ARCH appeared in at least 7. In 2025, RA Capital and OrbiMed each appeared in roughly 17 deals, Forbion in 15, Sanofi-related entities in 15, ARCH in 13, and several other investors appeared repeatedly.

So far in 2026, Janus Henderson and RA Capital each appear in 8 deals, OrbiMed in 7, Qiming and Frazier in 6 each, Forbion in 5, and several others in 3 to 5. That is not a picture of top investors pulling back.

What changed is the structure of top-investor activity. In 2024, the top 10 deals captured about 52% of capital. In 2025, the top 10 captured about 22%. So far in 2026, the top 10 captured about 37%. Top investors are still active, but they are spreading risk across more companies.

The answer is therefore that top investors are more active across the funding landscape, but less able or less willing to make the biotechnology market look strong through a few dominant rounds. That is a healthier structure than a market where one or two mega-financings define the entire year.

Which biotechnology subcategories are gaining momentum?

Therapeutics Discovery Platforms are the clearest subcategory gaining momentum in the biotechnology market. So far in 2026, they account for about 89% of capital and 85% of deals, up from about 82% of capital and 77% of deals over the comparable 2025 period.

That is the most important subcategory shift. Therapeutics Discovery Platforms raised about $5.2B across 46 deals in the first months of 2026, which makes them the center of gravity of the biotechnology market.

The momentum is not generic drug discovery. Investor attention is clustering around obesity and metabolic disease, autoimmune and inflammatory disease, antibody-drug conjugates, molecular glues, RNA and siRNA therapeutics, AI-enabled biology, neuropsychiatry, radiopharmaceuticals, and platform-enabled precision medicine.

That distinction matters because the market is not rewarding vague platform stories. It is rewarding platform-plus-program companies that connect scientific novelty to a disease area, clinical program, modality, or acquirable asset path.

Synthetic Biology Platforms show a small but interesting reappearance so far in 2026, with one $55M Series A deal. That is not enough to call broad momentum, but it suggests synthetic biology remains fundable when it is tied to therapeutic discovery rather than open-ended industrial platform narratives.

For a category-level view of which biotech submarkets are pulling capital, see the biotechnology market deck.

Which biotechnology subcategories are losing momentum?

Gene Editing Companies and Cell Therapy Developers are losing relative momentum in the biotechnology market so far in 2026, while Diagnostic Technology Firms and Bioprocessing Tool Providers remain mostly absent from the visible funding center.

The clearest recent decline is in Gene Editing Companies. Over the comparable period in 2025, gene editing represented about 10% of capital and 10% of deals. So far in 2026, it represents about 4% of capital and 6% of deals.

Cell Therapy Developers also lost relative share. Over the comparable period in 2025, cell therapy represented about 9% of capital and 13% of deals. So far in 2026, it represents about 6% of capital and 7% of deals.

This does not mean either category is dead. Gene editing and cell therapy still raise credible rounds, especially when companies have a clear asset, delivery logic, clinical focus, or strategic buyer rationale.

Diagnostics and bioprocessing tools are the most conspicuous weak categories in the visible venture data. Diagnostic Technology Firms had only one visible 2025 deal in the file and no identified year-to-date 2026 deals, while Bioprocessing Tool Providers appeared in the 2024 file with small rounds but not in the large-round center of 2025 or 2026.

The strongest conclusion is that capital is moving away from modality categories that require long validation arcs unless the company has a very clear path to clinical or strategic value. The biotechnology market is still ambitious, but it is more selective about where that ambition gets funded.

This chart, featured in our biotechnology market deck, looks at Vertex’s strategy in biotechnology

Which regions are gaining momentum in biotechnology funding?

Asia-Pacific is the region gaining the most momentum in biotechnology funding so far in 2026. Over the comparable period in 2025, Asia-Pacific accounted for only about 3% of capital and 4% of deals. So far in 2026, it accounts for about 19% of capital and 19% of deals.

That is the sharpest regional acceleration in the current-year evidence. Asia-Pacific moved from 2 deals and about $162M over the comparable 2025 period to 10 deals and about $1.1B so far in 2026.

The average Asia-Pacific round so far in 2026 is about $112M, close to North America’s roughly $113M. That means the region’s momentum is not just a cluster of small financings; it includes large institutional rounds.

North America remains strong, but it is not the region with the fastest momentum. Its capital share rose slightly from about 69% over the comparable 2025 period to about 72% so far in 2026, while its deal share fell from 75% to about 69%.

The practical takeaway is that North America remains the biotechnology market’s anchor, while Asia-Pacific is the clearest fresh growth signal. If that Asia-Pacific share persists, the regional map of private biotech funding will look less North America-only than it did in 2024.

For ongoing regional tracking across North America, Europe, and Asia-Pacific, see the market report covering biotechnology regional momentum.

Which regions are losing momentum in biotechnology funding?

Europe is losing momentum in the biotechnology market so far in 2026, at least relative to its strong showing in early and full-year 2025. Over the comparable period in 2025, Europe accounted for about 29% of capital and 21% of deals. So far in 2026, it accounts for about 10% of capital and 13% of deals.

The year-to-date comparison is the right starting point because the regional shift is recent and large. Europe raised about $1.8B across 10 deals over the comparable 2025 period, but only about $554M across 7 deals so far in 2026.

The average European round also fell from about $181M over the comparable 2025 period to about $79M so far in 2026. That suggests Europe’s early-2025 strength was driven by larger rounds that have not repeated at the same scale in the current window.

The full-year context prevents overreaction. Full-year 2025 was still a strong year for European biotech financing, with about $4.0B across 29 deals, representing 23% of capital and 21% of deals. Europe is not structurally absent from the biotechnology market.

The honest interpretation is that Europe’s 2025 momentum has not carried cleanly into the first months of 2026. The weakness may be timing, but the contrast with Asia-Pacific’s acceleration is too large to ignore.

Is biotechnology becoming more global or regionally concentrated?

The biotechnology market is becoming more global compared with 2024, but the freshest 2026 data shows globalization through Asia-Pacific rather than through a broad, evenly distributed world market. North America still dominates, but it no longer captures the overwhelming share seen in 2024.

The full-year comparison is the best structural read. In 2024, North America captured about 92% of capital and 78% of deals in the public dataset. In 2025, North America’s capital share fell to about 71%, Europe rose to about 23%, and Asia-Pacific reached about 6%.

The 2026 year-to-date evidence confirms globalization, but with a different regional mix. North America has about 72% of capital, Asia-Pacific has about 19%, and Europe has about 10%.

That means the biotechnology market is becoming more global, but not globally balanced. The visible funding base remains concentrated in North America, Europe, and Asia-Pacific, while Latin America, the Middle East, and Africa are absent from the reported funding splits.

The practical interpretation is that the market is less North America-only than it looked in 2024, but still anchored by mature biotech financing hubs. Asia-Pacific’s 2026 rise is the clearest sign of globalization, not proof that biotech capital is evenly distributed worldwide.

This chart, featured in our biotechnology market deck, shows how platform therapeutics have driven growth in the biotechnology market over time

Is biotechnology capital moving toward proven winners or new opportunities?

Biotechnology capital is moving toward both proven winners and new opportunities, but the balance has shifted slightly toward proven winners so far in 2026. Later-stage capital represents about 55% of year-to-date funding, while first financings represent about 43% of deals and 42% of capital.

That means the biotechnology market is still funding new opportunities at meaningful scale. A market where first financings take more than two-fifths of capital is not simply a rescue-financing environment for old portfolio companies.

At the same time, the largest capital share is leaning toward companies with more validation. Series B alone accounts for about $1.65B so far in 2026, and Series D+ rounds have the highest average and median round sizes in the stage mix.

The right reading is a barbell. Investors are still willing to fund new company formation where the science, assets, team, or sponsor quality are strong, but larger checks are more likely to go to companies with proof, clinical direction, or a clearer next value-creating milestone.

The biotechnology market is therefore not choosing between new opportunities and proven winners. It is financing both, while reserving the largest dollar commitments for companies that look more de-risked.

Our full market view on biotechnology follow-on activity tracks this split between first financings, follow-on rounds, and later-stage capital.

Is the biotechnology market becoming winner-takes-most?

The biotechnology market is not becoming more winner-takes-most in the strictest sense. It is still unequal, but it is less dominated by a few mega-rounds than it was in 2024.

The 2024 public dataset was highly concentrated. The top 10 deals captured about 52% of capital, the largest deal captured about 15%, and the bottom half of deals captured only about 4%. That made the market fragile to a few large financings.

Full-year 2025 looked much more distributed. The top 10 deals captured about 22% of capital, the largest deal captured about 4%, and the bottom half of deals captured about 28%.

So far in 2026, the market sits between those two conditions. The largest round accounts for about 5% of total capital, the top 3 for about 15%, the top 10 for about 37%, and the bottom half for about 30%.

The answer is that biotechnology funding remains skewed, as most venture markets are, but it is not currently winner-takes-most. The market is revealing a cohort of credible companies rather than crowning one obvious winner.

Is the next wave of biotechnology winners becoming visible?

The next wave of biotechnology winners is becoming visible, but it looks cohort-based rather than single-company-led. The lower largest-round concentration in 2026 means the market is not being defined by one flagship company in the way 2024 could be interpreted around a few very large launch rounds.

The visible winner set spans several themes. Investors are backing antibody-drug conjugates, immunology, RNA and siRNA therapeutics, obesity and metabolic disease, AI biology, gene therapy, cell therapy, neuropsychiatry, and precision medicine platforms.

That breadth matters. A single-category boom would be easier to identify, but also more fragile. The biotechnology market’s current structure suggests that investors are spreading conviction across multiple biological modalities and disease areas.

The strongest filter for future winners is no longer simply whether a company has a platform. The winning profile increasingly requires platform plus asset, platform plus disease area, platform plus clinical plan, or platform plus strategic buyer logic.

The next wave is therefore visible in outline, not fully settled. The companies most likely to separate themselves are the ones that can convert technical novelty into validated biology, credible clinical milestones, and repeat financing support.

As this chart shows, and as featured in our biotechnology market deck, search interest in biotech has been trending upward

Is the biotechnology funding landscape fragmenting or consolidating?

The biotechnology funding landscape is broadening, not simply consolidating. Deal count rose sharply from 2024 to 2025, and the year-to-date 2026 sample has more deals than the comparable 2025 period, even though total capital is slightly lower.

At the category level, however, the market is consolidating around Therapeutics Discovery Platforms. That category accounts for about 89% of year-to-date 2026 capital and 85% of deals, leaving every other subcategory with a much smaller visible funding footprint.

This creates a useful distinction. The company base is fragmenting because more companies can raise capital, but the category narrative is consolidating around therapeutics-oriented platforms with clear asset paths.

Investor participation also looks broad rather than narrow. Around 254 disclosed investor names appear in the 2026 year-to-date dataset, and leading funds are spread across many rounds rather than concentrating only in the top few deals.

The practical takeaway is that biotechnology is not fragmenting into a loose collection of unrelated micro-markets. It is broadening inside a dominant therapeutics-led frame. The market has more fundable companies, but the strongest funding logic is increasingly consistent.

Where is investor attention shifting in biotechnology?

Investor attention in biotechnology is shifting from platform potential toward platform plus asset. The companies raising the most credible rounds tend to connect technology to a disease area, modality, clinical program, or acquirable development path.

This is visible across the strongest 2025 and 2026 themes. Obesity and metabolic disease, autoimmune and inflammatory disease, antibody-drug conjugates, molecular glues, RNA and siRNA, radiopharmaceuticals, AI-enabled biology, and precision medicine all offer a clearer bridge between technical platform and future product.

That shift does not mean investors have stopped funding ambitious science. They are still funding bold technical ideas. The difference is that the winning story increasingly needs to show where the platform becomes an asset, where the asset becomes clinical proof, and where clinical proof becomes strategic value.

It also explains why diagnostics, bioprocessing, and broad tool platforms are less visible in the large-round funding center. Those businesses can be valuable, but the private biotech capital pool is currently paying most aggressively for therapeutic upside.

The best way to read the biotechnology market today is therefore to ask one question: what is the next value-creating proof point? The companies with a clear answer are the ones most likely to keep attracting capital.

For real-time tracking of biotechnology categories, stages, regional shifts, and investor attention, see our biotechnology market report.

All the funding deals in the biotech market from 2024 to Apr 2026

The table below lists every disclosed funding round in the supplied biotech funding dataset from 2024 through April 2026, covering therapeutics discovery platforms, cell therapy developers, gene editing companies, synthetic biology platforms, and bioprocessing tool providers.

Each row shows the company, fundraising date, what the company does, category, stage, round size, region, whether it was a first financing or follow-on, and disclosed tier-1 investors. For the broader investability view, see our market report.

This chart, featured in our biotechnology market deck, shows how at-home genetic testing technology has evolved over time

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living “market pitch” documents for emerging markets: from AI to synthetic biology and new proteins. Instead of digging through outdated PDFs, random blog posts, and hallucinated LLM answers, our clients get a clean, visual, always-updated view of what’s really happening. We map the key players, deals, regulations, metrics and signals that matter so you can decide faster whether a market is worth your time. Want to know more? Check out our about page.